Sonnet BioTherapeutics Holdings, Inc. short interest in 2024
In 2024, Sonnet BioTherapeutics Holdings, Inc.'s disclosed short interest ran from 5.34% of shares outstanding on 12 Jan 2024 to 2.08% on 31 Dec 2024, a change of -3.26 percentage points. The year's high was 18.16% on 15 Mar 2024 and its low 0.67% on 13 Sep 2024, averaging 8.42% across 15 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 29.29 days on 30 Apr 2024. Full history: Sonnet BioTherapeutics Holdings, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025
2024 in figures
- Start of year
- 5.34% (12 Jan 2024)
- End of year
- 2.08% (31 Dec 2024)
- Change
- -3.26 pp
- High
- 18.16% (15 Mar 2024)
- Low
- 0.67% (13 Sep 2024)
- Average
- 8.42%
- Highest days to cover
- 29.29 (30 Apr 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 5.34% | 3.34 | |
| 31 Jan 2024 | 5.45% | 11.71 | |
| 15 Feb 2024 | 7.56% | 5.21 | 10-Q filed, results (8-K) |
| 29 Feb 2024 | 8.28% | 2.75 | |
| 15 Mar 2024 | 18.16% | 1.57 | |
| 28 Mar 2024 | 14.73% | 5.79 | |
| 15 Apr 2024 | 13.82% | 16.70 | |
| 30 Apr 2024 | 13.04% | 29.29 | |
| 15 May 2024 | 13.12% | 23.67 | 10-Q filed, results (8-K) |
| 31 May 2024 | 11.06% | 10.29 | |
| 14 Jun 2024 | 10.88% | 14.96 | |
| 15 Aug 2024 | 1.26% | 1.00 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 0.85% | 1.00 | |
| 13 Sep 2024 | 0.67% | 1.00 | |
| 31 Dec 2024 | 2.08% | 1.00 | 10-K filed, results (8-K) |
See also: Sonnet BioTherapeutics Holdings, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.